Sildenafil Actavis

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

sildenafil

Available from:

Actavis Group PTC ehf

ATC code:

G04BE03

INN (International Name):

sildenafil

Therapeutic group:

Urološki

Therapeutic area:

Erektilna disfunkcija

Therapeutic indications:

Zdravljenje moških z erektilno disfunkcijo, ki ni sposobna doseči ali vzdrževati erekcije penisa, ki zadošča za zadovoljivo spolno delovanje. Da bi Sildenafil Actavis, da bo učinkovito, spolne stimulacije je potrebno.

Product summary:

Revision: 17

Authorization status:

Pooblaščeni

Authorization date:

2009-12-10

Patient Information leaflet

                                21
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Actavis Group PTC ehf.
220 Hafnarfjörður
Islandija
12.
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET
EU/1/09/595/001
[1 filmsko obložena tableta]
EU/1/09/595/002
[2 filmsko obloženi tableti]
EU/1/09/595/003
[4 filmsko obložene tablete]
EU/1/09/595/004
[8 filmsko obloženih tablet]
EU/1/09/595/005
[12 filmsko obloženih tablet]
EU/1/09/595/016
[24 filmsko obloženih tablet]
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Sildenafil Actavis 25 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
22
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOT
1.
IME ZDRAVILA
Sildenafil Actavis 25 mg tablete
sildenafil
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Actavis logo
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
23
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA
1.
IME ZDRAVILA
Sildenafil Actavis 50 mg filmsko obložene tablete
sildenafil
2.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN
Ena tableta vsebuje sildenafilijev citrat, ki ustreza 50 mg
sildenafila.
3.
SEZNAM POMOŽNIH SNOVI
Vsebuje laktozo monohidrat. Glejte navodilo za dodatne informacije.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
1 filmsko obložena tableta
2 filmsko obloženi tableti
4 filmsko obložene tablete
8 filmsko obloženih tablet
12 filmsko obloženih tablet
24 filmsko obloženih tablet
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
_ _
Peroralna uporaba
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
ZDRAVILO SHRANJUJTE NEDOSEGLJIVO OTROKOM!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 3
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATEK I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Sildenafil Actavis 25 mg filmsko obložene tablete
Sildenafil Actavis 50 mg filmsko obložene tablete
Sildenafil Actavis 100 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena tableta vsebuje sildenafil citrat, ki ustreza 25, 50 ali 100 mg
sildenafila.
Pomožna snov z znanim učinkom
Sildenafil Actavis 25 mg tablete
Ena tableta vsebuje 62,38 mg laktoze (v obliki monohidrata).
Sildenafil Actavis 50 mg tablete
Ena tableta vsebuje 124.76 mg laktoze (v obliki monohidrata).
Sildenafil Actavis 100 mg tablete
Ena tableta vsebuje 249.52 mg laktoze (v obliki monohidrata).
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Filmsko obložena tableta.
Sildenafil Actavis 25 mg filmsko obložene tablete
Filmsko obložene tablete Sildenafil Actavis 25 mg so modre,
eliptične, bikonveksne tablete, velike
10,0 x 5,0 mm in z oznako "SL25" na eni strani.
Sildenafil Actavis 50 mg filmsko obložene tablete
Filmsko obložene tablete Sildenafil Actavis 50 mg so modre,
eliptične, bikonveksne tablete, velike
13,0 x 6,5 mm in z oznako "SL50" na eni strani.
Sildenafil Actavis 100 mg filmsko obložene tablete
Filmsko obložene tablete Sildenafil Actavis 100 mg so modre,
eliptične, bikonveksne tablete, velike
17,0 x 8,5 mm in z oznako "SL100" na eni strani.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Sildenafil Actavis je indicirano pri odraslih moških z
erektilno disfunkcijo, tj. nezmožnostjo
doseči ali ohraniti erekcijo penisa, ki bi zadoščala za zadovoljivo
spolno dejavnost.
Da bi bilo zdravilo Sildenafil Actavis učinkovito, je potrebna spolna
stimulacija.
3
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
_Uporaba pri odraslih _
Priporočeni odmerek je 50 mg, uporabljen kot je potrebno, približno
eno uro pred spolno dejavnostjo.
Glede na učinkovitost in prenašanje je odmerek mogoče povečati na
100 mg ali zmanjšati na 25 mg.
Največji priporočeni odmerek je 100 mg. Največja priporočena
pogostnost odme
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 13-11-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 13-11-2023
Public Assessment Report Public Assessment Report Bulgarian 11-05-2015
Patient Information leaflet Patient Information leaflet Spanish 13-11-2023
Public Assessment Report Public Assessment Report Spanish 11-05-2015
Patient Information leaflet Patient Information leaflet Czech 13-11-2023
Public Assessment Report Public Assessment Report Czech 11-05-2015
Patient Information leaflet Patient Information leaflet Danish 13-11-2023
Public Assessment Report Public Assessment Report Danish 11-05-2015
Patient Information leaflet Patient Information leaflet German 13-11-2023
Public Assessment Report Public Assessment Report German 11-05-2015
Patient Information leaflet Patient Information leaflet Estonian 13-11-2023
Public Assessment Report Public Assessment Report Estonian 11-05-2015
Patient Information leaflet Patient Information leaflet Greek 13-11-2023
Public Assessment Report Public Assessment Report Greek 11-05-2015
Patient Information leaflet Patient Information leaflet English 13-11-2023
Public Assessment Report Public Assessment Report English 11-05-2015
Patient Information leaflet Patient Information leaflet French 13-11-2023
Public Assessment Report Public Assessment Report French 11-05-2015
Patient Information leaflet Patient Information leaflet Italian 13-11-2023
Public Assessment Report Public Assessment Report Italian 11-05-2015
Patient Information leaflet Patient Information leaflet Latvian 13-11-2023
Public Assessment Report Public Assessment Report Latvian 11-05-2015
Patient Information leaflet Patient Information leaflet Lithuanian 13-11-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 13-11-2023
Public Assessment Report Public Assessment Report Lithuanian 11-05-2015
Patient Information leaflet Patient Information leaflet Hungarian 13-11-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 13-11-2023
Public Assessment Report Public Assessment Report Hungarian 11-05-2015
Patient Information leaflet Patient Information leaflet Maltese 13-11-2023
Public Assessment Report Public Assessment Report Maltese 11-05-2015
Patient Information leaflet Patient Information leaflet Dutch 13-11-2023
Public Assessment Report Public Assessment Report Dutch 11-05-2015
Patient Information leaflet Patient Information leaflet Polish 13-11-2023
Public Assessment Report Public Assessment Report Polish 11-05-2015
Patient Information leaflet Patient Information leaflet Portuguese 13-11-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 13-11-2023
Public Assessment Report Public Assessment Report Portuguese 11-05-2015
Patient Information leaflet Patient Information leaflet Romanian 13-11-2023
Public Assessment Report Public Assessment Report Romanian 11-05-2015
Patient Information leaflet Patient Information leaflet Slovak 13-11-2023
Public Assessment Report Public Assessment Report Slovak 11-05-2015
Patient Information leaflet Patient Information leaflet Finnish 13-11-2023
Public Assessment Report Public Assessment Report Finnish 11-05-2015
Patient Information leaflet Patient Information leaflet Swedish 13-11-2023
Public Assessment Report Public Assessment Report Swedish 11-05-2015
Patient Information leaflet Patient Information leaflet Norwegian 13-11-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 13-11-2023
Patient Information leaflet Patient Information leaflet Icelandic 13-11-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 13-11-2023
Patient Information leaflet Patient Information leaflet Croatian 13-11-2023
Public Assessment Report Public Assessment Report Croatian 11-05-2015

Search alerts related to this product